TransMedics Group (TMDX) CEO receives major RSU and stock option grants
Rhea-AI Filing Summary
Hassanein Waleed H reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group President & CEO Waleed H. Hassanein received equity awards on July 10, 2026, including 49,669 restricted stock units and stock options for 112,984 shares at $71.23 per share, vesting monthly from April 2026 to April 2030.
Following these awards, he holds 171,093 shares directly and options on 112,984 shares, plus indirect holdings of 150,000 shares through the Hassanein 2026 Qualified Annuity Trust and 345,009 shares through the Waleed H. Hassanein Revocable Trust; a 150,000‑share transfer between these trusts was a change in the form of beneficial ownership exempt under Rule 16a-13.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Hassanein Waleed H
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 112,984 | $0.00 | -- |
| Grant/Award | Common Stock | 49,669 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 112,984 shares (Direct);
Common Stock — 171,093 shares (Direct);
Common Stock — 345,009 shares (Indirect, By the Waleed H. Hassanein Revocable Trust)
Footnotes (1)
- Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Reflects a prior transfer of 150,000 shares of the Issuer's common stock from the Waleed H. Hassanein Revocable Trust to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change in the form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service.
Key Figures
RSU grant: 49,669 shares
Option grant size: 112,984 shares
Option exercise price: $71.23 per share
+3 more
6 metrics
RSU grant
49,669 shares
Restricted stock units granted to Waleed H. Hassanein on July 10, 2026
Option grant size
112,984 shares
Stock options granted to Hassanein on July 10, 2026
Option exercise price
$71.23 per share
Exercise price of newly granted stock options
Direct shares after grant
171,093 shares
Common stock directly held by Hassanein following RSU grant
Hassanein 2026 Qualified Annuity Trust
150,000 shares
Common stock held indirectly through the Qualified Annuity Trust
Revocable Trust holdings
345,009 shares
Common stock held indirectly through the Waleed H. Hassanein Revocable Trust
Key Terms
restricted stock units ("RSUs"), Rule 16a-13, Qualified Annuity Trust, Stock Option (Right to Buy)
4 terms
restricted stock units ("RSUs") financial
"Consists of 49,669 restricted stock units ("RSUs"). Each RSU represents a contingent right"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Rule 16a-13 regulatory
"was exempt under Rule 16a-13 of the Securities Exchange Act of 1934"
Qualified Annuity Trust financial
"to the Hassanein 2026 Qualified Annuity Trust. The transfer constituted only a change"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)","
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did TransMedics (TMDX) CEO Waleed Hassanein receive on July 10, 2026?
Waleed Hassanein received 49,669 restricted stock units and stock options for 112,984 shares of TransMedics common stock. The options carry a $71.23 exercise price and represent a compensation grant rather than an open-market purchase or sale.
How do the new stock options for TransMedics (TMDX) CEO vest?
The new options for 112,984 shares vest at 2.0833% of the total grant each month after April 10, 2026. Vesting continues until the award is fully vested on April 10, 2030, contingent on Hassanein’s continued service.
What are the key details of the restricted stock units granted to the TransMedics (TMDX) CEO?
The award consists of 49,669 RSUs, each representing a contingent right to receive one share of TransMedics common stock. These units were granted at no purchase price as part of equity compensation to President & CEO Waleed Hassanein.
What is the exercise price and expiration date of the new TransMedics (TMDX) stock options granted to the CEO?
The options cover 112,984 shares at an exercise price of $71.23 per share and expire on July 10, 2036. They vest monthly between April 2026 and April 2030, subject to continued service.